Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease
JA Obeso, MC Rodríguez‐Oroz… - … : official journal of the …, 2008 - Wiley Online Library
The basal ganglia (BG) are a highly organized network, where different parts are activated
for specific functions and circumstances. The BG are involved in movement control, as well …
for specific functions and circumstances. The BG are involved in movement control, as well …
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease
l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic treatment of
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …
[HTML][HTML] Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
MA Cenci - Frontiers in neurology, 2014 - frontiersin.org
The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's
disease (PD) for over 40 years. However, the response to this treatment changes with …
disease (PD) for over 40 years. However, the response to this treatment changes with …
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders
Dopamine is an essential neurotransmitter for many brain functions, and its dysfunction has
been implicated in both neurological and psychiatric disorders. Parkinson's disease is an …
been implicated in both neurological and psychiatric disorders. Parkinson's disease is an …
Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease
F Alonso-Frech, I Zamarbide, M Alegre… - Brain, 2006 - academic.oup.com
The pathophysiology of levodopa-induced dyskinesias (LID) in Parkinson's disease is not
well understood. We have recorded local field potentials (LFP) from macroelectrodes …
well understood. We have recorded local field potentials (LFP) from macroelectrodes …
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
MA Cenci, K Skovgård, P Odin - Neuropharmacology, 2022 - Elsevier
Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Objective: Striatal serotonin projections have been implicated in levodopa‐induced
dyskinesia by providing an unregulated source of dopamine release. We set out to …
dyskinesia by providing an unregulated source of dopamine release. We set out to …
Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice
MA Cenci, M Lundblad - Current protocols in Neuroscience, 2007 - Wiley Online Library
This unit provides detailed protocols for establishing rodent models of l‐DOPA‐induced
dyskinesia. The 6‐hydroxydopamine (6‐OHDA) lesion procedure is described in more detail …
dyskinesia. The 6‐hydroxydopamine (6‐OHDA) lesion procedure is described in more detail …
l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the …
HS Lindgren, DR Andersson… - Journal of …, 2010 - Wiley Online Library
J. Neurochem.(2010) 112, 1465–1476. Abstract l‐DOPA‐induced dyskinesia in Parkinson's
disease is associated with large increases in brain dopamine (DA) levels following drug …
disease is associated with large increases in brain dopamine (DA) levels following drug …